ImmuONE is a biotech company specializing in human alveolar macrophage responses, epithelial cell culture platforms, and testing services. They offer innovative solutions for inhalation toxicology, irritation sensitization, alveolar clearance, and inflammation. Their respiratory tissue models closely resemble lung physiology, providing relevant and reliable results. ImmuONE is committed to developing sustainable technologies for human-relevant safety assessments and animal product-free cell models.

ImmuONE

ImmuONE specialises in human alveolar macrophage responses, epithelial cell culture platforms and testing services. Our respiratory tissue models closely resemble lung physiology to provide relevant, reliable, and reproducible results.
 
ImmuONE is partnered with the industry and academia to develop sustainable technologies for the future to support human-relevant, mechanistic driven safety assessments and develop animal product-free cell models.
 
We offer a range of standard and bespoke assessments for inhalation safety assessment needs. ImmuONE provides innovative solutions for inhalation toxicology, irritation sensitization, alveolar clearance, inflammation and can tailor to your inhalation safety assessment needs. 
 
We invite you to learn more about how our products and services can help your business by visiting our website: www.immuone.com
 
Follow us on Twitter:
@ImmuONE

#UKTech #BioTech: 🧬 UK-based biotech I
ImmuONE, a spin-out from the University of Hertfordshire, just secured a £2 million #investment 💰. 

This #funding was provided by the MEIF Proof of Concept & Early Stage Fund, managed by Mercia Ventures, as part of the Midlands Engine Investment Fund (MEIF), along with support from Mercia's EIS funds and Pioneer Group. 🚀

 💉🔬Learn more about ImmuONE's approach to eradicate animal testing: https://lnkd.in/gdCWYU7d

#FemaleFounders #WomenInTech #UK #BioTechnology #News #TechNews #Startup #FundingNews #Technology #Innovation #InvestmentNews

Abigail Martin Victoria Hutter Hannah Tapsell Chapman Mark Wilcockson Pauline Rawsterne

📢 ImmuONE has raised £2m from Mercia Ventures and Pioneer Group 
 
💥 It has been an absolute pleasure working alongside the dynamic founding duo of Abigail and Victoria over the last few months. I'm very excited to see how far this business can go over the coming years.

👋 Welcome to industry leaders, Kevin and Richard, who we are delighted to have joining the board to help the team navigate this next phase of growth. ImmuONE is so fortunate to have such deep expertise from both the UK and the US.

🤝 Plus, lovely as always to work on another co-investment with Dr Imelda and Glenn!

🙏 Special thanks to Stephanie from Innovate UK and Pete from the University of Hertfordshire for all their hard work in supporting ImmuONE to date.

Midlands Engine Investment Fund #MEIF #Venture #VentureCapital #Entrepreneurship #LifeSciences #Innovation #CRO #ScaleUp #Investment #MidlandsEngine #EastMidlands

🔬 ImmuONE has raised a £2m investment to move into new headquarters in Milton Keynes and new laboratories in Stevenage to meet the growing demand.

The two scientists behind ImmuONE's unique technology, Dr Abigail Martin and Professor Victoria Hutter, have developed a 3D human lung model that can assess the safety of new drugs without the use of animal testing. It also enables companies developing new products such as drugs, chemicals or cosmetics to meet legal requirements by showing they are safe for consumption and wider use.

They secured backing from the MEIF Proof of Concept & Early Stage Fund, which is managed by Mercia Ventures and part of the Midlands Engine Investment Fund, Mercia’s EIS funds and Pioneer Group

More ⏬ 

#MEIF #BioTech #MiltonKeynes #Investment #VentureCapital #Entrepreneurship #Testing #AnimalFreeApproaches #Innovation #EIS

Are you searching for a promising in vitro screening tool for the safety assessment of inhaled products? Not to toot our own 📯, but at ImmuONE, high-throughput models for assessing inflammatory endpoints in the deep lung are our speciality. We run a wide variety of macrophage assessments covering endpoints for cell health, biochemical and protein markers. We've also got an expanding range of high content imaging assays (e.g. morph_ONE), which delve deep into the lung to offer detailed insight into the effects of inhaled substances on lung macrophages and their morphology. 

Lung epithelial cells are also our jam - using our model ImmuLUNG™, which combines alveolar epithelial and alveolar macrophage-like cells, we can evaluate the effects of compounds on epithelial barrier integrity. Want to know more? Join our webinar on Innovative Approaches to Inhalation Safety: Unveiling Cutting-Edge Tools where you’ll hear from our speakers Prof. Victoria Hutter and Dr Louis Scott about the myriad of ways that ImmuONE can answer your lung toxicity screening needs. 

📅 8 November ⏰ 14:00-14:50 BST Register here: https://lnkd.in/eZiAjNrX

#CellPainting #InhalationSafety #LungToxicity #NAMs #Toxicology #EpithelialCells

🎉 ImmuONE is delighted to announce a £2 million UK Venture Capitalists and US Angel investment 💸 from Mercia Ventures and Pioneer Group! The new funding injection has enabled us to move to our new lab in Stevenage and hire new team members 🙋 to help us expand.

Here’s our journey so far:
🧫 Developed a 3D in vitro human lung and immune cell model as part of Abigail Martin’s PhD supervised by Victoria Hutter
🐾 Realised the potential of the model as an alternative to animal testing
✔️ Validated the market with funding from Innovate UK’s iCURE programme
💼 Abigail Martin & Victoria Hutter founded ImmuONE in 2019
👩🦰 Achieved more than 20 customers worldwide
💰 Generated over £1m in revenue by 2023

And now: 💸 £2 million investment – the sky’s the limit!

Stay tuned to find out more about ImmuONE’s scale-up phase!

Psst… and to find out more about the services that ImmuONE offers companies to test the impact of inhaled products on the lungs, join our webinar 🖥️ on 8 November from ⏰ 14:00-14:50 BST.

https://lnkd.in/e4yMhKCR

☕ Join us for a chat over coffee with Rhamiya Mahendran, our amazing Application Scientist at ImmuONE!  
 
In our recent coffee chat, Rhamiya shared her fascinating journey within ImmuONE, her passion for cell culture, and a sneak peek into an upcoming webinar on ImmuONE’s tools.  
 
Read here: https://lnkd.in/ej9gaawW
 
Stay tuned for ImmuONE's webinar on Nov 8, "Unveiling next-generation tools for inhalation risk assessment." 🗓️ Get ready for an engaging discussion on human-relevant tools and addressing safety assessments! Register here: https://lnkd.in/eZiAjNrX 

 #animalfreeapproaches #LifeAtImmuONE #BiotechInnovation

If foamy macrophage responses are halting your risk assessments, and you’d like to better understand the immune reaction of the human lung to your inhaled product, ImmuONE could have the answer.

With morph_ONE, we provide detailed phenotypic profiles to decipher how macrophages interact with your compounds, enabling informed and efficient development decisions. This advanced tool not only distinguishes between various alveolar macrophage responses but also pinpoints safe from unsafe compounds, like those inducing phospholipidosis or apoptosis. We have additional models of the deep lung that focus on epithelial cell morphology and also offer bespoke services based on your needs.

Join Prof Victoria Hutter and Dr Louis Scott at our webinar: Unveiling Next-Generation Tools for Inhalation Risk Assessment, where they’ll be presenting our range of solutions.

📅 8 November
⏰ 14:00-14:50 BST
Register here: https://lnkd.in/eZiAjNrX
#CellPainting #InhalationSafety #LungToxicity #NAMs #Toxicology

Looking for an in vitro solution for lung toxicity and inhalation risk assessments? Join us on 8 November for our first webinar on: Unveiling next-generation tools for inhalation risk assessment

You’ll find out about:
🧫 ImmuONE’s unique in vitro screening tools to support the safety assessment of new inhaled products, allowing earlier, more informed compound selection and development decisions.
🧫 ImmuONE’s morph_ONE HCIA cell painting assay, which serves as a predictive high-throughput screening tool, differentiating alveolar macrophage response profiles.
🧫 How ImmuONE uses our proprietary products, ImmuPHAGE™ and ImmuLUNG™, to deliver bespoke inhalation safety assessments

Our speakers Prof. Dr Victoria Hutter and Dr Louis Scott will demonstrate how our products and services can help clients from a wide range of industries (e.g. pharmaceuticals, agrochemicals, consumer goods) achieve their research goals. We’ll also be discussing opportunities to partner with ImmuONE. 🤝

After the talk, you’ll get the opportunity to ask any burning questions and connect with our speakers to discuss your specific needs.

📅 8 November
⏰ 14:00-14:50 BST
Register here: https://lnkd.in/eZiAjNrX

🌟**Join Our Team at ImmuONE!**🌟

Are you a passionate advocate for cutting-edge biotechnology and humane alternatives to animal testing? Do you possess a blend of expertise in inhalation toxicology and an innate ability to forge strategic business relationships?

🔍 We're on the Hunt for: A Business Development & Events Coordinator.

Why work with ImmuONE?
🔬 Pioneers in human alveolar macrophage responses & epithelial cell culture platforms.
🌏 We work alongside industry leaders and academic institutions to reshape the future of safety assessments.
🚀 Experience growth, development, and global travel opportunities.
🤝 Play an instrumental role in cultivating a community that thrives on biotech advancements.

For a detailed overview of the role, benefits, and requirements, refer to the attached job advert. If this resonates with your career aspirations and you believe you can add significant value to our team, we'd love to hear from you.

📅 Application Deadline: 16/10/2023

📩 Apply at: HR@Immuone.com

Join us in our mission to "Make Every Breath Safe" and be a part of the NAMs revolution!

#HiringNow #Biotech #InhalationToxicology #BusinessDevelopment #EventsCoordination

https://lnkd.in/g_AAXHja

Exciting news! 🎉 

We are delighted to announce that along with Kadans Science Partner, ImmuONE have moved to a new state of the art lab 🔬 and office at Sycamore House in Stevenage. 😃 

Our new lab and office allow ImmuONE to develop our ideas into life changing realities through scale up and further development of our products and services ensuring our innovative in vitro lung models continue to provide safe, accurate, and effective methods to assess the risk of chemical products on the human lung. 

Working closely on this project was ImmuONE’s Project Management Intern Idara Isa and Executive Personal Assistant Kar Chi Lee. Idara and Kar Chi worked diligently on the development of our new lab and are excited to give you an insight into our state-of-the-art space. Take a look at Idara and Kar Chi’s journey to the new lab!

#biotech #scaleup #toxicology

COM:IMMUONE

ImmuONE

name

homepage url

country

linkedin url

employee count

sector

industry

Description

investor of

Metrics